Skorzewiak / Shutterstock.com
1 October 2024NewsEuropeLiz Hockley

UK judge ends J&J unit’s hopes of reviving Stelara patent

Janssen Biotech denied permission to appeal invalidation of ustekinumab patent | Samsung Bioepis convinced UK court to revoke patent in July.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
14 June 2023   Deal thought to be aimed at helping pharma giant attain sales target as patents start to expire | Israeli drugmaker will join with Icelandic firm to unveil a copycat version of blockbuster treatment by 2025.
Big Pharma
25 May 2023   Amgen can market biosimilar version of Stelara from January 2025 | J&J had alleged infringement of two Stelara patents.

More on this story

Americas
14 June 2023   Deal thought to be aimed at helping pharma giant attain sales target as patents start to expire | Israeli drugmaker will join with Icelandic firm to unveil a copycat version of blockbuster treatment by 2025.
Big Pharma
25 May 2023   Amgen can market biosimilar version of Stelara from January 2025 | J&J had alleged infringement of two Stelara patents.

More on this story

Americas
14 June 2023   Deal thought to be aimed at helping pharma giant attain sales target as patents start to expire | Israeli drugmaker will join with Icelandic firm to unveil a copycat version of blockbuster treatment by 2025.
Big Pharma
25 May 2023   Amgen can market biosimilar version of Stelara from January 2025 | J&J had alleged infringement of two Stelara patents.